Chemoradiation Treatment with or without Concurrent Tumor-Treating Fields (TTFields) in Patients with Newly Diagnosed Glioblastoma (GBM)

Molecular Markers Impacting Survival in Patients Receiving Concurrent Chemoradiation and Tumor-Treating Fields (TTF) in Patients with Newly Diagnosed Glioblastoma: Secondary Analysis of SPARE Trial

A Propensity-Matched Study to Evaluate PTEN and TP53 Mutations as Predictive Biomarkers of Survival in Newly Diagnosed IDH-Wildtype Glioblastoma after Tumor Treating Fields

Tumor Treating Fields (TTFields) Enhance the Efficacy of Temozolomide and Lomustine in Glioblastoma Cell Lines

Tumor Treating Fields (TTFields) Concomitant with PARP Inhibitors for Treatment of Ovarian Cancer Cell Lines

PI3K Inhibition Sensitized Cancerous Cells to Tumor Treating Fields (TTFields)

Enhancing Cancer Cell Membrane Permeability by Application of Tumor Treating Fields (TTFields)

Tumor Treating Fields (TTFields) Delivery to Macrophages Promotes a Pro-Inflammatory Phenotype

Preclinical Evaluation of Tumor Treating Fields Combined with Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR)

Sensitivity of TTFields Dose Distribution in the Lungs to the Deviations in Array Placement

Examining Array Layouts for Targeting a Single Lung with TTFields

Multiinstitutional Patterns of Use and Compliance with Tumor Treating Fields for Patients with Unresectable Malignant Pleural Mesothelioma

Feasibility of TTFields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Real-World Data

KEYNOTE B36: A Pilot Study of First-line Tumor Treating Fields (150 kHz) Plus Pembrolizumab for Advanced or Metastatic Non-small Cell Lung Cancer

Tumor Treating Fields (TTFields) Application Promotes a Pro-inflammatory Phenotype in Macrophages

Cancer Cells May be Re-sensitized to Tumor Treating Fields (TTFields) Through Inhibition of the PI3K/AKT/mTOR Pathway

The PROTECT Study: A phase II, open-label trial of prophylactic skin toxicity therapy with clindamycin and triamcinolone in patients with glioblastoma treated with tumor-treating fields

PANOVA-3: A phase 3 study of tumor-treating fields with gemcitabine and nab-paclitaxel for frontline treatment of locally advanced pancreatic adenocarcinoma

Self-assembling nanoparticles: A novel approach for targeted cancer treatment using tumor treating fields

Tumor treating fields enhance cellular drug uptake in mesothelioma cell lines

Blood brain barrier (BBB) disruption by tumor treating fields (TTFields) in a human 3D in vitro model

Tumor Treating Fields (TTFields) promote a pro-inflammatory phenotype in macrophages

Application of Tumor Treating Fields (TTFields) to cancer cells enhances their membrane permeability

Tumor treating fields induce DNA damage and apoptosis in medulloblastoma

Transcriptomics analysis for identification of pathways involved in the response to Tumor Treating Fields (TTFields)

Spatial omic changes of malignant pleural mesothelioma following treatment using tumor-treating fields

Synergic antitumoral activity of TTFields stimulation and Chloride Intracellular Channel 1 (CLIC1) inhibition in human glioblastoma primary culture

Concomitant treatment of ovarian cell lines with Tumor Treating Fields (TTFields) and PARP inhibitors

Inhibition of PI3K sensitized cancer cells to Tumor Treating Fields (TTFields)

Tumor Treating Fields reduce cellular survival of human mesenchymal stromal cells via apoptosis and senescence induction

Tumor treating fields suppression of ciliogenesis enhances temozolomide toxicity

Tumor Treating Fields in combination with radiation cause significant delay in tumor growth in in-vivo mice model significant delay in tumor growth in in-vivo mice model

Tumor treating fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord

Impact of model inaccuracy on dose estimation in TTFields therapy

Efficacy of concomitant application of Tumor Treating Fields (TTFields), temozolomide and lomustine in glioblastoma cancer cells in vitro

PANOVA-3: A phase 3 study of tumor treating fields with gemcitabine and nab-paclitaxel for front-line treatment of locally advanced pancreatic adenocarcinoma

Breaching the blood brain barrier (BBB) by Tumor Treating Fields (TTFields) could be a novel chemotherapeutic delivery strategy

Effect of duty cycles of tumor-treating fields on glioblastoma cell and normal brain organoids

Tumor treating fields combined with concurrent radiotherapy for newly diagnosed glioblastoma with rapid early tumor progression

PriCoTTF trial: a phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

Synergic antitumoral activity of TTFields stimulation and Chloride Intracellular Channel 1 (CLIC1) inhibition in human glioblastoma primary culture

Enhancing membrane permeability of cancer cells through delivery of Tumor Treating Fields (TTFields)

Inhibition of PI3K restores cancer cell sensitivity to Tumor Treating Fields (TTFields)

Effects of Tumor Treating Fields in combination with temozolomide and lomustine on glioblastoma cancer cells in vitro

Risk assessment scale of scalp adverse events prior to TTFields

Trident phase 3 trial (EF-32): first-line Tumor Treating Fields (TTFields; 200 kHz) concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastoma

Final estimates of french health utilities for glioblastoma patients using ttfields

Retrospective analysis of using radiotherapy with concurrent Temozolomide and Tumor Treating Fields for chinese patients with newly diagnosed glioblastoma

Phase 2 study of pembrolizumab plus TTFields plus temozolomide in patients with newly diagnosed glioblastoma (2-THE-TOP)

DNA damage response inhibitor combinations to enhance TTFields potency using clinically relevant ex-vivo glioblastoma models

Prostaglandin E receptor 3 mediates resistance to Tumor Treating Fields in glioblastoma cells

Induction of anti-tumor immunity by Tumor Treating Fields (TTFields) in glioblastoma

Real-world retrospective analysis of tumor treating fields in the treatment of high-grade glioma based on chinese population

Synergistic effect by targeting TTFields induced cell cycle effects

Tumor Treating Fields (TTFields) impair the survival and migratory potential of human mesenchymal stromal cells

Validating skullremodeling surgery configuration to enhance TTFields for first recurrence glioblastoma with computational modeling

Tolerability of Tumor Treating Fields (TTFields) in pediatric high-grade glioma patients illustrated by post-market surveillance data

Feasibility and safety of TTFields therapy for glioblastoma patients with ventriculoperitoneal shunt

Telehealth to overcome pandemic/geographic barriers: experience managing care of patients with glioblastoma (GBM) receiving Tumor Treating Fields (TTFields) therapy

Factors guiding the initiation of Tumor Treating Fields (TTFields; 200 kHz) therapy for glioblastoma: self-reported patient and oncologist perspectives

SPARE trial: scalp sparing radiation with concurrent temozolomide and Tumor Treating Fields (200 kHz) for patients with newly diagnosed glioblastoma

Computational anatomic analysis to evaluate the impact of Tumor Treating Fields (TTFields) on brain anatomy

Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma may increase the rate of distant recurrence

Tumour treating fields (TTFields) therapy for glioblastoma: a quantitative and qualitative summary of research and advances in our understanding

Concurrent TTFields (200 kHz) with chemoradiation for patients with newly diagnosed glioblastoma may increase the rate of pseudoprogression: secondary analysis of a pilot clinical trial

Evidence that recurrence patterns of TTFields treated patients affect patient outcomes: post-hoc analysis of the randomized phase 3 EF-14 trial

Safety and efficacy of TTFields for newly diagnosed GBM in Japanese patients using the Novo-TTF System: a prospective post-approval study

Developing the framework for Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord

Mechanism of action and associated effects of Tumor Treating Fields (TTFields) on living cells using simulations

Combination of Tumor Treating Fields (TTFields) with lomustine and temozolomide - a multicentric real world analysis in newly diagnosed glioblastoma

Patient-oriented communication strategies improve acceptance of tumour-treating fields in primary and recurrent glioblastoma

Tumor treating fields (TTFields) in combination with sorafenib inhibit hepatocellular carcinoma in vitro and in vivo

PANOVA-3: A phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic adenocarcinoma

In vitro Tumor Treating Fields (TTFields) reduce proliferation and alter MLH1 expression in temozolomide resistant (TMZR) patient-derived glioblastoma (GBM) cells

Assessment of Tumor Treating Fields (TTFields) combined with trichostatin A (TSA) in patient-derived glioblastoma (GBM) cells

Phase 2 study of pembrolizumab plus TTFields plus temozolomide in patients with newly diagnosed glioblastoma (2-THE-TOP)

TRIDENT phase 3 trial (EF-32): first-line Tumor Treating Fields (TTFields; 200 kHz) concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly-diagnosed glioblastoma

Tumor-Treating Fields Combined with Second-line Chemotherapy in Recurrent Glioblastoma: A Matched Retrospective Study

Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma may increase the rate of distant recurrence

PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

Dosimetric impact of tumor treating fields on concurrent radiation therapy for pediatric brain tumors

Retrospective Analysis of Using Radiotherapy with Concurrent Temozolomide and Tumor Treating Fields for Chinese Patients with Newly Diagnosed Glioblastoma

Prostaglandin E receptor 3 (PTGER3) regulates resistance to Tumor Treating Fields (TTFields) in glioblastoma cells

Reduced cancer cell sensitivity to Tumor Treating Fields (TTFields) through activation of the PI3K/AKT/mTOR signaling pathway can be mitigated using PI3K inhibitors or PI3K/mTOR dual inhibitors

Tumor Treating Fields in combination with the TERT-inhibitor eribulin have synergistic antiproliferative effects on human glioblastoma cells

Increasing cancer cell membrane permeability through application of Tumor Treating Fields (TTFields)

Application of Tumor Treating Fields (TTFields) to the head and torso of mice with the dedicated inovivo system

Developing the novel combination therapy options for cancer therapy using Tumor Treating Fields together with the chemo agents targeting the replication stress pathway

Induction of Anti-Tumor Immunity by Tumor Treating Fields (TTFields) in Glioblastoma

TTFields Treatment of Gliosarcoma and Recurrent Anaplastic Oligodendroglioma

Tumor treating fields (TTF) as maintenance therapy for an oligodendroglioma case and long-term follow-up

Understanding factors that influence the decision of accepting Tumor Treating Fields (TTF) therapy

Effect of duration of Tumor Treating Fields therapy on cellularity distributions beyond T1w MRI contrast enhancing margin at autopsy in glioma patients: preliminary results

Factors Guiding the Initiation of Tumor Treating Fields (TTFields; 200 kHz) Therapy for Glioblastoma: Self-reported Patient and Oncologist Perspectives

Real-World Retrospective Analysis of Tumor Treating Fields in The Treatment of High-Grade Glioma Based on Chinese Population

Delayed pseudoprogression in glioblastoma patients treated with TTFields: A report of two cases

A Longitudinal Observational Study of Exercise Behavior in Glioblastoma Patients Treated with Tumor-Treating Fields

Quality of life of patients with newly diagnosed glioblastoma during TTFields therapy in routine clinical care: first results of the TIGER study

SPARE trial: Scalp-sparing radiation with concurrent temozolomide and Tumor Treating Fields for patients with newly diagnosed glioblastoma

Concurrent TTFields (200 kHz) with chemoradiation for patients with newly diagnosed glioblastoma may increase the rate of pseudoprogression: analysis of a pilot clinical trial

Developing the framework for Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord

Mechanism of action and associated effects of Tumor Treating Fields (TTFields) on living cells using simulations

The safety profile of Tumor Treating Fields (TTFields; 200 kHz) concomitant with ventriculo-peritoneal shunts in patients with glioblastoma and hydrocephalus

Mechanism of action of Tumor Treating Fields (TTFields) in combination with sorafenib for treatment of hepatocellular carcinoma

Comprehensive approaches to enhancing Tumor Treating Fields dose at the tumor

Framework for dosimetry and treatment planning of TTFields

Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord

Creating computational models for planning TTFields treatment for tumors in the infratentorial brain

Impact of model inaccuracy on dose estimation in TTFields therapy

Treating spinal-cord tumors with TTFields — A simulation study

Segmentation of the upper torso for lung cancer TTFields treatment planning

Tumor Treating Fields synergistically enhances cell death in non-small cell lung and pancreatic cancer cells treated with the combination of radiation and chemo agents that interfere with DNA replication fork stability

Activated phosphoinositide 3-kinase/AKT/mTOR signaling confers resistance to Tumor Treating Fields (TTFields)

Impact of Tumor Treating Fields (TTFields) on DNA damage repair in mesothelioma

SPARE trial: Scalp sparing radiation with concurrent temozolomide and Tumor Treating Fields (200 kHz) for patients with newly diagnosed glioblastoma

Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma may increase the rate of distant recurrence

Combination treatment of irradiation and Tumor Treating Fields for human glioblastoma cells

Concurrent TTFields (200 kHz) with chemoradiation for patients with newly diagnosed glioblastoma may increase the rate of pseudoprogression: Analysis of a pilot clinical trial

HEPANOVA: Final efficacy and safety results from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma

Underlining mechanism for the efficacy of Tumor Treating Fields (TTFields) concomitant with sorafenib for treatment of hepatocellular carcinoma

Health-related quality of life for glioblastoma short and long-term survivors receiving treatment with TTFields

Scalp-sparing radiation with concurrent temozolomide and Tumor Treating Fields (SPARE) for patients with newly diagnosed glioblastoma

Transient opening of the blood brain barrier by Tumor Treating Fields (TTFields)

Rapid transformation of TTFields care-delivery during COVID-19 pandemic to optimize treatment of patients with glioblastoma (GBM)

Patient-derived metastatic renal carcinoma cells are highly sensitive to in vitro Tumor Treating Fields (TTFields)

Valproic acid (VPA) combined with Tumor Treating Fields (TTFields) in vitro decreases cellular proliferation and increases clonogenic potential of glioblastoma (GBM) cells

Targeting replication stress pathway provides an avenue for novel combination therapy options including TTFields plus chemo agents which increase replication stress

Effectiveness of Tumor Treating Fields (TTFields) in combination with sorafenib for treatment of hepatocellular carcinoma in vitro and in vivo

Antiproliferative effects of Tumor Treating Fields in human mesothelioma cell lines

Concomitant dexamethasone treatment and Tumor Treating Fields induced cell death in glioblastoma

Efficacy of Tumor Treating Fields (TTFields) in mesothelioma is associated with reduced capacity for DNA damage repair

Long-duration term TTFields treatment of glioblastoma cells induces cell death

inovivo: a dedicated system for delivery of therapeutic level Tumor Treating Fields (TTFields) to mice

Targeting Akt signaling pathway potentiates the antitumor effect of Tumor Treating Fields (TTFields) in vitro

The distribution of Tumor Treating Fields is affected by cell confluence and pores in the membrane

A novel immunoregulatory role of tumor Treating Fields (TTFields) on macrophage polarization

Tumor Treating Fields triggers OFD1 removal from primary cilia to promote glioma cell survival

Tumor Treating Fields induce cellular and morphologic changes including disruption of intercellular communication networks in malignant pleural mesothelioma

French health utilities for patients with glioblastoma using TTFields

Contemporary clinical practice guidelines for the management of glioblastoma: an international survey

Tumor Treating Fields induce DNA damage and apoptosis in medulloblastoma

Lung cancer TTFields treatment planning sensitivity to errors in torso segmentation

A method for infratentorial structures segmentation for Tumor Treating Fields treatment planning

EF-32 (TRIDENT): A pivotal randomized trial of radiation therapy concomitant with temozolomide +/- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma

Drug loaded nanoparticle targeting of pancreatic cancer using Tumor Treating Fields (TTFields)

Long-term application of TTFields in anaplastic astrocytoma - a case study

Radiosurgery followed by Tumor Treating Fields for brain metastases (1-10) from NSCLC in the phase 3 METIS trial

Radiological response to TTFields plus chemotherapy for malignant pleural mesothelioma from the phase 2 STELLAR trial

Pooled safety analysis of clinical trials delivering Tumor Treating Fields (TTFields) to the upper torso

Effectiveness of Tumor Treating Fields plus cisplatin/pemetrexed combination in mesothelioma, in vitro and in vivo

Computational simulations on safety of Tumor Treating Fields delivered to the lungs in mesothelioma and NSCLC

Evaluation of the safety of Tumor Treating Fields (TTFields) application to the torso – in vivo studies

Tumor Treating Fields (150 kHz) concurrent with immune check point inhibitors for stage 4 non-small cell lung cancer (NSCLC) in phase 3 LUNAR study

Genetic markers correlated with progression-free survival times in glioblastoma patients undergoing treatment with Tumor Treating Fields

PTEN mutations predict benefit from Tumor-Treating Fields therapy in patients with recurrent glioblastoma

Therapeutic implications of conditional vulnerabilities caused by TTFields exposure in novel combination therapies for non-small cell lung cancer and brain metastases from non-small cell lung cancer

Real-world perspectives: Tumor Treating Fields (TTFields) utility to optimize treatment of patients with glioblastoma (GBM) amidst COVID-19 pandemic

Tumor Treating Fields for glioblastoma therapy during the COVID-19 pandemic: Expert consensus on use and experience

Combining the glioblastoma cell membrane-permeabilizing effect of Tumor Treating Fields (TTFields) with withaferin A (and other) chemotherapy

Innovative computational platform addresses prostaglandin E receptor 3 as the master regulator mediating resistance to Tumor Treating Fields in glioblastoma cells

Updates for a phase 2 open-labeled study of pembrolizumab plus TTFields plus maintenance temozolomide in patients with newly diagnosed glioblastoma (2-THE-TOP)

Phase I study of the safety and immunogenicity of personalized neoantigen vaccines and Tumor Treating Fields in patients with newly diagnosed glioblastoma

Scalp sparing radiation with concurrent temozolomide and Tumor Treatment Fields (SPARE) for patients with newly diagnosed glioblastoma

A prospective, observational study evaluating the safety and quality of life of Tumor Treating Fields in Chinese glioblastoma patients

A phase II trial of Tumor Treating Fields (TTFields) concomitant with radiosurgery for the treatment of recurrent, bevacizumab-naïve glioblastoma

First safety analysis of anaplastic meningioma patients treated with Tumor Treating Fields (TTFields)

Efficacy of TTFields in elderly patients with newly diagnosed glioblastoma (GBM) – sub-group analysis of the EF-14 trial

Long-term survival in glioblastoma patients after Tumor Treating Fields (TTFields) therapy

TTFields in routine clinical care of newly diagnosed GBM patients in Germany – first report on the fully enrolled TIGER study population

Overall survival of newly diagnosed glioblastoma patients treated by standard therapy in comparison to standard therapy plus Tumor Treating Fields

Phase 3 TRIDENT trial: Concomitant radiation therapy (RT) and temozolomide +/- Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma

EF-19, a post-approval registry study of Tumor Treating Fields (TTFields) in recurrent glioblastoma (rGBM)

PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

Increasing Tumor Treating Fields (TTFields) efficacy by targeting the G2 cell cycle checkpoint with combined Wee1 or Chk1 inhibitors in glioblastoma cell lines

Valproic acid enhances anti-proliferative effects of Tumor Treating Fields on patient-derived gliosarcoma cells in vitro

Increased cancer cell permeability following Tumor Treating Fields (TTFields) application in vitro

The inovivo system: a novel preclinical tool for in vivo delivery of Tumor Treating Fields (TTFields)

Dual activation of the cGAS-STING pathway and AIM2-induced pyroptosis by Tumor-Treating Fields produces anti-tumor immunity in glioblastoma

Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord

Effects of TTFields usage and duration of usage on cellularity and Ki67 distributions at autopsy

Impact of gender on Tumor Treating Fields compliance in patients with glioblastoma

First health utilities of glioblastoma patients using TTFields treatment

Tumor Treating Fields in meningioma

Changes in magnetic resonance imaging after proton boost therapy for glioblastoma with and without Tumor Treating Fields therapy

Delayed pseudoprogression in two patients undergoing TTFields treatment for newly diagnosed glioblastoma

The effect of cell confluence on the distribution of Tumor Treating Fields

Study of local perturbation in computational modelling on Tumor Treating Fields (TTFields) therapy

Comparison of symptom burden and associated impact on daily life in glioblastoma patients treated with and without Tumor Treating Fields

New therapeutic delivery methods for Tumor-Treating Fields for higher efficacy

Radiosurgery followed by Tumor Treating Fields for brain metastases (1-10) from NSCLC in the phase 3 METIS trial

Enhancing Tumor Treating Fields therapy for recurrent glioblastoma with targeted and individualized skull remodeling surgery. A multi-center randomized phase 2 trial

Phase 2 trial of Tumor Treating Fields (TTFields) plus radiation therapy (RT) plus temozolamide (TMZ) compared to RT plus temozolomide in newly diagnosed glioblastoma (ndGBM)

Long-lasting Tumor Treating Fields (TTFields) stimulation of glioblastoma primary culture damages preferentially fully differentiated cancer cells

Tumor Treating Fields (TTFields) hinder glioma cell motility through regulation of microtubule and actin dynamics

Effectiveness and safety of Tumor Treating Fields (150 kHz) plus cisplatin or pemetrexed combination in mesothelioma: in vitro and in vivo findings

The impact of electric conductivity of tissues on the electric field intensity and power density during TTFields therapy for glioblastoma

Sensitivity of TTFields numerical simulations to model inaccuracies

Evidence that recurrence patterns of TTFields treated patients affect patient outcome: Post-hoc analysis of the randomized phase 3 EF-14 trial

A machine learning based approach for rapidly estimating Tumor Treating Fields distributions in the body

A simulation-based method for planning delivery of TTFields to brain tumors

Tumor Treating Fields disrupt the CDK-E2F-Rb axis: Implications for the use of radiation and targeted agents against E2F and CDK4/6 during TTFields treatment

Safety and effectiveness of Tumor Treating Fields (TTFields; 150 kHz) and sorafenib combination treatment in hepatocellular carcinoma in vitro and in vivo

Updated safety and feasibility study of concurrent Tumor Treating Fields (TTFields) and radiation therapy for newly diagnosed glioblastoma

Global Post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice

EF-19: A post-approval registry study of Tumor Treating Fields (TTFields) in recurrent glioblastoma (rGBM)

Developing a radiotherapy workflow for glioblastoma patients treated in presence of Tumor Treating Fields arrays

Efficacy of Tumor Treating Fields (TTFields) in elderly patients with newly diagnosed glioblastoma (GBM): Sub-group analysis of the phase 3 EF-14 trial

The long tail problem: novel parametric methods still underestimate long-term conditional survival in glioblastoma

A phase III trial of Tumor Treating Fields with nab-paclitaxel and gemcitabine for front-line treatment of locally-advanced pancreatic adenocarcinoma (LAPC): PANOVA-3

Clinical outcomes of the combination of bevacizumab and TTFields in patients with recurrent glioblastoma: Results of a phase II clinical trial

Post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice

Tumor Treating Fields effects on the blood-brain barrier in vitro and in vivo

Updated safety/feasibility study of concurrent Tumor Treating Fields (TTFields) and radiation therapy for newly diagnosed glioblastoma

EF-19, a post-approval registry study of Tumor Treating Fields (TTFields) in recurrent glioblastoma (rGBM)

Efficacy of tumor treating fields (TTFields) in elderly patients with newly diagnosed glioblastoma (GBM): Sub-group analysis of the phase III EF-14 trial

Compatibility of topical agents with Tumor Treating Fields (TTFields) for treatment of associated skin events in glioblastoma (GBM)

Phase III TRIDENT trial: Radiation and temozolomide +/- Tumor Treating Fields in newly diagnosed glioblastoma

TTFields dose distribution alters tumor growth patterns: An imaging-based analysis of the randomized phase 3 EF-14 trial

Increasing TTFields treatment efficacy by targeting G2 cell cycle checkpoint

What electric field strength is necessary for maximum Tumor-Treating Fields efficacy

Proteomic analysis of lung cancer cells exposed to Tumor Treating Fields identified the dysregulation of the E2F-Rb-CDK4/6 axis rendering tumor cells susceptible to novel combination therapies that target CDK4/6 and/or E2F

In vitro and in vivo evidence for the safety and efficacy of Tumor Treating Fields (TTFields) in combination with sorafenib

Efficacy of Tumor Treating Fields (TTFields) in combination with cisplatin or pemetrexed for the treatment of mesothelioma in vitro and in vivo

In vitro TTFields enhance the response to temozolomide or radiation in GBM cells from a newly diagnosed patient

Tumor Treating Fields (TTFields) elicit an anti-tumor immune response and in combination enhance anti-PD-1 treatment efficacy

Overall survival of glioblastoma patients treated by standard therapy in comparison to standard therapy plus Tumor Treating Fields

Cancer cell lines meta-analysis according to both short-term and long-term responses to Tumor Treating Fields (TTFields)

The inovivo system: A novel in vivo tool for the application of Tumor Treating Fields (TTFields) to mice

Combined in vitro TTFields and paclitaxel reduce proliferation and clonogenicity in non-small cell lung cancer (NSCLC) cells from a patient previously treated with standard-of-care

Influence of the thermal and electric properties of biological tissues on the maximum temperature during TTFields therapy

Transducer array layouts for treating head and neck cancer with TTFields

The influence of computational model inaccuracies on calculated electric field distributions when simulating TTFields therapy

Co-activation of STING pathway and immunogenic cell death by Tumor Treating Fields produces effective antitumor immunity in glioblastoma

Tumor Treating Fields (TTFields) induce cancer cell permeability in vitro

HDAC6 inhibitors may enhance TTFields toxicity to glioma cells by altering primary cilia

Blood brain barrier opening by TTFields: a future CNS drug delivery strategy

Combining the glioblastoma cell membrane-permeabilizing effect of Tumor Treating Fields with chemotherapy

Effects of tumor treating fields (TTFields) on dendritic cells functionality

Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial

PriCoTTF trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

Optimizing Tumor Treating Fields therapy for recurrent glioblastoma with targeted and individualized skull remodeling surgery. A multi-center randomized phase 2 trial

HEPANOVA: Interim safety analysis from a phase 2 study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC)

Concurrent Tumor Treating Fields (TTFields) and radiation therapy for newly diagnosed glioblastoma: A safety and feasibility study

EF-19 - A post-approval registry study of TTFields for the treatment of recurrent glioblastoma (GBM)

Efficacy of TTFields in elderly patients with newly diagnosed glioblastoma (GBM): Sub-group analysis of the EF-14 trial

Post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice

Impact of innovative educational approaches to enhance patient and caregiver understanding of Tumor Treating Fields (TTFields) for glioblastoma implications for outcomes

Budget impact analysis of TTFields + platinum-based therapy for first-line malignant pleural mesothelioma

Immunomodulatory effects of Tumor Treating Fields (TTFields) on colon cancer models

Tumor Treating Fields (TTFields; 150 kHz) and FOLFOX combination treatment effects on gastric cancer in vitro

In vitro and in vivo efficacy and safety of Tumor Treating Fields (TTFields) and sorafenib combination in hepatocellular carcinoma

A multicenter phase II trial of Tumor Treating Fields plus chemotherapy for first-line treatment of gastric adenocarcinoma

Phase II HEPANOVA trial of Tumor Treating Fields concomitant with sorafenib for advanced hepatocellular carcinoma

PANOVA-3: A phase III study of Tumor Treating Fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma (LAPC)